NYR – Supplementary NYR-BI03 Studies Confirm Strong Cardioprotection

Highlights:
•Nyrada successfully completes supplementary preclinical studies, further supporting NYR-BI03’s efficacy in treating ischemia-reperfusion injury associated with heart attack.
•Echocardiography assessment showed significant improvements in heart function and structure following NYR-BI03 treatment.
•Blood biomarkers of injury also showed significant improvements following NYR-BI03 treatment.
•No FDA-approved drugs specifically target ischemia-reperfusion injury, highlighting a significant unmet clinical need.
•Global market for myocardial infarction therapies to reach US$3.7 billion by 20321.
•4Phase I clinical trial for NYR-BI03 scheduled to commence in late 2024.